258 / 328
MEETING MINUTES
I.
Welcome and Introductions
The Expert Review Panel Co-Chair Terry Koerner welcomed Expert Review Panel members, initiated
introductions, and discussed with the panel the goal of the meeting.
II.
Review of AOAC Volunteer Policies & Expert Review Panel Process Overview and Guidelines
Deborah McKenzie presented a brief overview of AOAC Volunteer Policies, Volunteer Acceptance Agreement
and Expert Review Panel Policies and Procedures which included Volunteer Conflicts of Interest, Policy on the
Use of the Association, Name, Initials, Identifying Insignia, Letterhead, and Business Cards, Antitrust Policy
Statement and Guidelines, and the Volunteer Acceptance Form (VAF). All members of the ERP were required
to submit and sign the Volunteer Acceptance Form. In addition, she also presented an overview of the ERP
process including meeting logistics, consensus, First Action to Final Action requirements, and documentation.
III.
Review of Methods
All ERP members presented a review and discussed the proposed collaborative study manuscript for
OMAMAN-19: R-Biopharm, Competitive Enzyme Immunoassay Based on the R5 Monoclonal Antibody to
Determine Partially Hydrolysed Gluten in Foods Containing Wheat, Rye, and Barley. The method author Dr.
Markus Lacorn and Patricia Meinhardt of R-Biopharm were present and able to address questions and
concerns of the ERP members. A summary of comments were provided to the ERP members and the method
author.
1By consensus, the ERP presented the following motions for OMAMAN-19.
MOTION:
Motion by Wehling; Second by Boison, to move OMAMAN-19 to AOAC First Action Official Methods status.
Consensus demonstrated by: (Unanimous) in favor, 0 opposed, and 0 abstentions.
Motion Passed.
MOTION:
Motion by Garber; Second by Wehling, First to Final action requirements for OMAMAN-19 require single
laboratory validation data showing at and below 20 mg/kg.
Consensus demonstrated by: (Unanimous) in favor, 0 opposed, and 0 abstentions.
Motion Passed.
All ERP members presented a review and discussed the proposed collaborative study manuscript for
OMAMAN-20: R-Biopharm, Qualitative Detection of Gluten on Surfaces and In Processed and Non-Processed
Products by R5 Immuno-Chromatographic Dip Stick. The method author Dr. Markus Lacorn of R-Biopharm was
present and able to address questions and concerns of the ERP members. A summary of comments were
provided to the ERP members and the method author.
2By consensus, the ERP presented the following
motions for OMAMAN-20.
MOTION:
Motion by Don; Second by Yeung, to table the discussion and decision on OMAMAN-20 pending R-
Biopharm’s response to the ERP comments.
Consensus demonstrated by: (Unanimous) in favor, 0 opposed, and 0 abstentions.
Motion Passed.
IV.
Discuss Final Action Requirements for First Action Official Methods (if applicable)
No further action was discussed at this time. The First to Final Action requirements set for OMAMAN-19 were
noted in the meeting minutes above.
V.
Adjournment:
Meeting adjourned at 5:22pm
1
Attachment 1: Summary of Expert Reviewer Comments for OMAMAN-19
2
Attachment 2: Summary of Expert Reviewer Comments for OMAMAN-20
ERP PROFILE SUMMARIES
218